肿瘤标志物CA19-9、CA125、AFP及CEA联合检测在胆管癌诊断中的价值

Significance of the detection of tumor markers CA19-9,CA125,AFP and CEA in the diagnosis of cholangiocarcinoma

目的:探讨肿瘤标志物CA19-9、CA125、AFP及CEA联合检测在胆管癌临床诊断中的价值。方法:用电化学发光免疫分析仪对50例胆管癌、63例良性胆道疾病患者和200例正常对照组进行血清肿瘤标志物CA19-9、CA125、AFP及CEA检测。结果:胆管癌患者血清中CA19-9、CA125、AFP及CEA的阳性表达高于正常组(P<0.001),而CA19-9、AFP及CEA的阳性表达高于良性胆道疾病组(P<0.05)。四项肿瘤标记物联合检测的敏感性为96.0%,特异性为83.7%,阳性预测值为52.8%,阴性预测值为99.1%,准确性为85.6%。结论:CA19-9对胆管癌具有较好的诊断价值,联合检测肿瘤标志物CA19-9、CA125、AFP及CEA可以提高对胆管癌诊断的敏感性。

Objective： To investigate the clinical value of the combined detection tumor markers of CA19-9, CA125, AFP and CEA in diagnosing cholangiocarcinoma. Methods. The serum CA19-9, CA125, AFP and CEA in 50 cases of cholangiocarcinoma and 63 cases of benign biliary tract diseases and 200 healthy persons （used as the normal control group） were detected with the electrochemical luminescence immunity analyzer. Results： The positive expressions of CA19-9, CA125, AFP and CEA in the patients with cholangiocarcinoma were obviously higher than those in the normal control group （P〈0. 001）, and also significantly higher than those in the patients with benign biliary tract diseases （P〈0.05）. The sensitive rate, specificity, positive predictive value, predictive value and accuracy rate were 96.0%, 83.7%, 52.8%/%, 99.1% and 85.6% resp negative ectively. Conclusion： CA19-9 has good diagnostic value for cholangiocarcinoma, the combination detections of the four indicators can improve clinical diagnostic sensitivities for cholangiocarcinoma.